ChemoFilter: A Novel Catheter Device to Enable High-Dose Chemotherapy Treatment
ChemoFilter:一种新型导管装置,可实现高剂量化疗治疗
基本信息
- 批准号:8647078
- 负责人:
- 金额:$ 22.5万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-08-01 至 2016-07-31
- 项目状态:已结题
- 来源:
- 关键词:AchievementAddressAnimal ModelAnimalsArteriesBindingBiocompatibleBloodBlood CirculationBlood coagulationCancer EtiologyCathetersCause of DeathCessation of lifeChemistryChemotherapy-Oncologic ProcedureClinicalComplete Blood CountControl AnimalDevicesDialysis procedureDiarrheaDiseaseDisease remissionDoseDoxorubicinDrug Delivery SystemsDrug toxicityExtracorporeal DialysisFamily suidaeFiltrationGoalsHeart failureHematologic AgentsHemodialysisHepaticHigh Dose ChemotherapyHumanIACUCImplantIn VitroInferior vena cava structureInterventional radiologyIntravenousLaboratoriesLeadLeftLegal patentLiver neoplasmsLyticMalignant NeoplasmsMalignant neoplasm of liverMeasuresMedical DeviceMetabolismMethodsModelingMonitorOrganPatientsPharmaceutical PreparationsPharmacotherapyPhasePhlebographyProceduresRandomized Controlled TrialsRenal functionRouteSerumSimulateSmall Business Technology Transfer ResearchStreamSymptomsSystemic venous structureTechnologyTestingTherapeuticThrombosisTimeToxic effectToxicity due to chemotherapyTumor EscapeUltrasonographyUnited StatesVeinsVenousVenous Pressure levelcancer therapychemical bindingchemotherapycostdosagefeedingfightinghemodynamicshepatic veinimplantable deviceimprovedin vivointerestliver functionminimally invasivemortalitynovelpreventprototypepublic health relevanceresponsetreatment durationtumor
项目摘要
!
Project Summary:
Intravenous dosing of drugs for applications ranging from cancer chemotherapy to anti-microbials to
lytic (blood clot dissolving) agents is limited by systemic toxicity. Currently, the only ways to remove drugs from
the blood are through natural metabolism or costly impractical measures such as dialysis. Despite intense
focus on targeted drug delivery agents, these therapies are costly and rare, especially considering traditional
older drugs are low-cost yet clinically effective, and can be used in a targeted manner with higher efficacy if
they could be filtered out of the body after their effect in order to prevent toxicities. Intra-arterial chemotherapy
(IAC) is performed in interventional radiology (IR), enabling direct delivery of chemotherapy to tumors by
guiding micro-catheters into the arteries feeding these tumors. IAC with Doxorubicin (Dox) has proven to be a
successful method demonstrating mortality benefit in randomized controlled trials (1, 2) for treating non-
operative primary liver cancer, the third leading cause of cancer deaths worldwide, due to its ability to
maximize drug dosage to tumor while limiting systemic dose and toxicity. Nonetheless, up to 50% of the chemo
in IAC escapes the tumor and causes toxicity, such as heart failure, thereby limiting high-dose Dox therapy.
Dialysis-style filtration has been shown to increase tumor response and long term remission with limited toxicity
(3-7), but this method is unsafe, costly, and time consuming. We propose the use of ChemoFilter, a catheter
filtration device that would be percutaneously placed similar to a central line under x-ray guidance within the
vein draining the organ undergoing IAC in order to capture this escaping chemotherapy from the bloodstream
via chemical binding mechanisms. The device would be removed from the patient within 60 minutes (no
implant) at the end of the IAC procedure.
In this Phase I STTR proposal, we seek to validate ChemoFilter in-vivo. We have demonstrated in-vitro
proof-of-concept with our benchtop flow model resulting in Provisional U.S. Patents, and functional catheter
prototypes, which are ready to be tested in a swine animal model (IACUC approved, n=24) simulating hepatic
IAC. We will demonstrate that in-vivo the ChemoFilter catheter will be: (a) efficacious in rapid, high-capacity
binding of Dox from the bloodstream (Specific Aim 1), (b) safely deployed and biocompatible (Specific Aim 2),
and (c) able to reduce short-term toxicities (Specific Aim 3). Achievement of these specific aims will lead to
FDA 510(k) approval for ChemoFilter as an effective, low-cost, minimally invasive, disposable catheter device
that could enable chemotherapy toxicity reduction and high-dose treatments in humans, which will be validated
in a Phase II STTR study. ChemoFilter ultimately will lead to a new paradigm in drug therapy as a platform
technology for potentially any drug-disease combination (both oncologic and non-oncologic) treated by intra-
arterial or even intravenous routes.
!
!
!
项目概要:
静脉给药的药物应用范围从癌症化疗到抗微生物剂,
溶解(血凝块溶解)剂受到全身毒性的限制。目前,唯一的方法,以消除药物从
血液是通过自然代谢或昂贵的不切实际的措施,如透析。尽管激烈
这些治疗方法都是昂贵且罕见的,特别是考虑到传统的
较老的药物成本低,但临床有效,可以有针对性地使用,疗效更高,如果
它们可以在作用后被过滤出体外,以防止毒性。动脉内化疗
(IAC)在介入放射学(IR)中进行,通过以下方式将化疗直接输送到肿瘤
引导微导管进入供应这些肿瘤的动脉。IAC与阿霉素(Dox)已被证明是一种
在随机对照试验中成功证明了治疗非糖尿病的死亡率获益(1,2)
手术性原发性肝癌是全球癌症死亡的第三大原因,由于其能够
最大限度地增加肿瘤的药物剂量,同时限制全身剂量和毒性。尽管如此,高达50%的化疗
在IAC中,药物逃逸肿瘤并引起毒性,如心力衰竭,从而限制了高剂量Dox治疗。
透析式滤过已被证明可以增加肿瘤反应和长期缓解,毒性有限
(3-7)但这种方法不安全、成本高且耗时。我们建议使用ChemoFilter导管
过滤装置,其将在X射线引导下类似于中心线被永久放置在
静脉引流接受IAC的器官,以捕获血流中逃逸的化疗药物
通过化学结合机制。该装置将在60分钟内从患者体内取出(不
在IAC手术结束时植入)。
在本I期STTR提案中,我们寻求在体内确认ChemoFilter。我们已经在体外实验中证明
通过我们的台式流动模型进行概念验证,获得临时美国专利和功能性导管
原型,准备在模拟肝脏的猪动物模型(IACUC批准,n=24)中进行测试
IAC。我们将证明体内ChemoFilter导管将:(a)有效快速、高容量
从血流中结合Dox(特定目标1),(B)安全展开和生物相容(特定目标2),
和(c)能够减少短期毒性(具体目标3)。实现这些具体目标将导致
FDA 510(k)批准ChemoFilter作为一种有效、低成本、微创、一次性导管器械
这可以使化疗毒性降低和高剂量治疗的人类,这将得到验证
在一项II期STTR研究中ChemoFilter作为一个平台,最终将成为药物治疗的新范式。
用于潜在的任何药物-疾病组合(肿瘤和非肿瘤)的技术,
动脉甚至静脉途径。
!
!
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Anand S Patel其他文献
Anand S Patel的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 22.5万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 22.5万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 22.5万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 22.5万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 22.5万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 22.5万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 22.5万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 22.5万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 22.5万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 22.5万 - 项目类别:
Research Grant